Instil Bio closed at $6.97 on Nov 5, down 0.29%, 55.7% below its 52-week closing high. Volume of 69.0K shares was 1.12× its 20-day average (close to normal).
Split-adjusted performance: +1.0% over one month, -13.2% over six months, -54.0% over one year.
Short interest was 170.5K shares at the Oct 15 settlement, up 7.2% from the prior report (6.8% of float, 6.8 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TILInstil Bio | $6.97 | −0.29% | −13.2% | — | — | — | $47.3M | |
| IMAImageneBio | $4.08 | −0.49% | −31.0% | — | — | — | $46.3M | Compare |
| GRMLGreenland Mines | $3.62 | −7.42% | — | — | — | — | $49.5M | Compare |
| KLRSKalaris Therapeutics | $2.10 | +3.96% | −59.2% | — | — | — | $50.0M | Compare |
| ELOXEloxx Pharmaceuticals | $12.59 | −1.18% | — | — | — | — | $50.8M | Compare |
| CRBUCaribou Biosciences | $0.4069 | −8.44% | −78.4% | −43.8% | −1619.9% | — | $43.6M | Compare |
| INKTMiNK Therapeutics | $10.10 | −4.70% | −9.7% | — | — | — | $51.6M | Compare |
| LONALeonaBio | $4.32 | −5.40% | −56.2% | — | — | — | $40.7M | Compare |
| EXOZeXoZymes | $4.11 | −4.64% | −58.9% | — | — | — | $38.2M | Compare |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
